DexCom Inc. ($DXCM) Stock Forecast: Up 4.1% Today

What is DexCom Inc.?

DexCom, Inc. (NASDAQ: DXCM) specializes in glucose monitoring systems, specifically the G6 and G7 devices. The company's stock saw a notable bullish movement in the market today.

Why is DexCom Inc. going up?

DXCM stock is up 4.1% on Dec 10, 2025 15:35

• The rise in DXCM's stock price could be linked to investors potentially seeing recent class action lawsuits and allegations as temporary hurdles that DexCom can navigate.
• Despite legal concerns regarding unauthorized design alterations to its devices and resulting reliability and health issues, investors may have confidence in DexCom's ability to tackle these challenges and uphold its market position.
• Investor faith in DXCM may also be bolstered by positive updates or announcements regarding the company's product pipeline, partnerships, or financial performance, overshadowing the short-term legal uncertainties.
• Overall, today's bullish movement in DXCM's stock suggests that investors are concentrating on the company's long-term growth potential and resilience in the face of legal obstacles, rather than solely dwelling on the ongoing lawsuits and allegations.

DXCM Price Chart

DXCM Technical Analysis

DXCM News

DXCM DEADLINE: DexCom, Inc. Investors Encouraged to Contact Kirby McInerney LLP Before Looming Deadline in Lawsuit

Investors in DexCom, Inc. (NASDAQ:DXCM) are urged to contact Kirby McInerney LLP regarding a securities fraud class action lawsuit, with a lead plaintiff deadline of December 26, 2025. The lawsuit alleges that DexCom made unauthorized design changes to its G6 and G7 glucose monitors, leading to inaccurate readings, health risks, and a decline in stock prices due to regulatory scrutiny and downgrades. The firm is seeking to represent investors who suffered losses during the period of January 8, 2024, through September 17, 2025.

https://fox40.com/business/press-releases/accesswire/1116151/dxcm-deadline-dexcom-inc-investors-encouraged-to-contact-kirby-mcinerney-llp-before-looming-deadline-in-lawsuit

Shareholders SueWallSt in New Class Action Against DexCom, Inc. - Act Now

A class action lawsuit has been filed against DexCom, Inc. on behalf of investors who reportedly lost money due to alleged securities fraud between January 8, 2024, and September 17, 2025. Investors affected by these losses are encouraged to contact Levi & Korsinsky for more information and to take action. The firm, with a history of securing large sums for shareholders, specializes in complex securities litigation.

https://www.news10.com/business/press-releases/accesswire/1116017/shareholders-suewallst-in-new-class-action-against-dexcom-inc-act-now

DXCM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that DexCom, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against DexCom, Inc. (NASDAQ: DXCM) on behalf of investors who purchased securities between January 8, 2024, and September 17, 2025. The lawsuit alleges that DexCom made materially false and misleading statements regarding unauthorized design changes to its G6 and G7 devices, rendering them less reliable and posing health risks to users. Investors who suffered losses are encouraged to join the lawsuit and have until December 26, 2025, to request to be appointed as lead plaintiff.

https://www.abc27.com/business/press-releases/globenewswire/9595476/dxcm-investor-alert-bronstein-gewirtz-grossman-llc-announces-that-dexcom-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit

DXCM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that DexCom, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against DexCom, Inc. (NASDAQ: DXCM) on behalf of investors who purchased securities between January 8, 2024, and September 17, 2025. The lawsuit alleges that DexCom made materially false and misleading statements regarding unauthorized design changes to its G6 and G7 devices, leading to reliability issues and health risks. Investors who suffered losses have until December 26, 2025, to request to be appointed as lead plaintiff.

https://ktla.com/business/press-releases/globenewswire/9595476/dxcm-investor-alert-bronstein-gewirtz-grossman-llc-announces-that-dexcom-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit

Holzer & Holzer, LLC Reminds Investors of Upcoming Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against MoonLake Immunotherapeutics (MLTX), DexCom, Inc. (DXCM), and Synopsys, Inc. (SNPS)

Holzer & Holzer, LLC is reminding investors of upcoming lead plaintiff deadlines in shareholder class action lawsuits against MoonLake Immunotherapeutics (MLTX), DexCom, Inc. (DXCM), and Synopsys, Inc. (SNPS). The lawsuits allege materially false and/or misleading statements by the respective companies regarding their business practices and products. Investors who suffered significant losses during specific class periods are encouraged to contact the firm to discuss their legal rights and seek to be appointed lead plaintiff.

https://www.globenewswire.com/news-release/2025/12/09/3202617/0/en/holzer-holzer-llc-reminds-investors-of-upcoming-lead-plaintiff-deadlines-in-shareholder-class-action-lawsuits-against-moonlake-immunotherapeutics-mltx-dexcom-inc-dxcm-and-synopsys-.html

Trending Today

Pfizer Inc. ($PFE) Stock Forecast: Down 5.1% Today

Humana Inc. ($HUM) Stock Forecast: Down 5.1% Today

Cytokinetics, Incorporated ($CYTK) Stock Forecast: Down 5.0% Today

S&P 500 Index ($SPX) Index Forecast: Down 0.8% Today

Apache Corporation ($APA) Stock Forecast: Down 5.1% Today

Wix.com Ltd. ($WIX) Stock Forecast: Up 5.1% Today

Rivian Automotive Inc. ($RIVN) Stock Forecast: Down 6.0% Today

Aurora Cannabis Inc. ($ACB) Stock Forecast: Up 5.1% Today

Centene Corporation ($CNC) Stock Forecast: Down 5.0% Today

Riot Platforms, Inc. ($RIOT) Stock Forecast: Down 5.6% Today

DexCom Inc. Price History

10.11.2025 - DXCM Stock was up 4.1%

• The rise in DXCM's stock price could be linked to investors potentially seeing recent class action lawsuits and allegations as temporary hurdles that DexCom can navigate.
• Despite legal concerns regarding unauthorized design alterations to its devices and resulting reliability and health issues, investors may have confidence in DexCom's ability to tackle these challenges and uphold its market position.
• Investor faith in DXCM may also be bolstered by positive updates or announcements regarding the company's product pipeline, partnerships, or financial performance, overshadowing the short-term legal uncertainties.
• Overall, today's bullish movement in DXCM's stock suggests that investors are concentrating on the company's long-term growth potential and resilience in the face of legal obstacles, rather than solely dwelling on the ongoing lawsuits and allegations.

11.10.2025 - DXCM Stock was up 5.7%

• The rise in DXCM's stock value may stem from investors perceiving the recent securities fraud class action lawsuits as temporary obstacles that DexCom will likely surmount.
• Despite the legal hurdles, investor confidence in DexCom's capacity to innovate within the healthcare technology industry could be bolstering the stock's performance.
• Growing interest in the stock might also be a result of speculation surrounding potential resolutions or settlements related to the securities law violations, fostering a positive outlook among traders.

11.10.2025 - DXCM Stock was up 5.1%

• Today's bullish movement in DXCM's stock may be linked to the favorable market response to its robust Q3 growth and expanded CGM coverage, positioning the company for ongoing adoption despite growing competition.
• Despite facing legal challenges such as securities fraud class action lawsuits and allegations of securities law violations, investors appear to be more focused on the company's growth potential and momentum driven by innovation.
• While some investors have taken a bearish stance in the options market, this sentiment does not seem to have significantly impacted DXCM's stock performance today, as the overall optimistic outlook on the company's future prospects overshadowed these issues.

13.10.2025 - DXCM Stock was up 5.1%

• An upcoming lead plaintiff deadline in a securities lawsuit may have initially caused volatility in the stock.
• Despite bearish opinions in the options market, positive news surrounding DXCM's strong growth in Q3 and focus on innovation likely reassured investors and supported the bullish movement.
• Ongoing securities fraud class action lawsuits and legal reminders could have led to short-term fluctuations. However, the overall positive view on DXCM's performance and market position has been more prominent, driving the bullish trend.
• Investors appear to be placing more emphasis on the company's growth potential and competitive standing rather than its legal challenges, leading to an increase in the stock price.

31.06.2025 - DXCM Stock was down 8.0%

• Despite surpassing Q2 earnings and increasing 2025 sales outlook, DXCM's stock faced a decline as margin pressure impacted investor sentiment.
• The company's strong financial results were overshadowed by worries about margins, resulting in the bearish movement of the stock.
• Expectations for better performance beyond the reported figures might have led to disillusionment among investors, contributing to the drop in stock value.

19.08.2025 - DXCM Stock was down 5.5%

• The decline in DXCM stock today could be linked to a recent claim suggesting that the company sold faulty G7 devices flagged by the FDA. Incidents of hospitalizations and alleged deaths associated with the G7 device may have raised concerns among investors about the product's quality and regulatory consequences.
• Ongoing investigations by legal firms looking into potential claims and breaches of fiduciary duties by DexCom's executives could have contributed to the negative sentiment towards the stock, prompting the bearish market performance.
• Investor response may be tied to uncertainties and legal inquiries surrounding DexCom, Inc., influencing the stock's trajectory as stakeholders weigh the potential risks and ramifications of the investigations on the company's future prospects.

25.08.2025 - DXCM Stock was down 5.0%

• An ongoing investigation related to investor claims may have introduced uncertainty and pessimism into the stock, resulting in its bearish movement.
• Increased bearish options activity by well-funded investors might have exacerbated the downward trend of DXCM shares.
• Allegations surrounding the sale of faulty G7 devices by Dexcom, leading to adverse events and FDA citations for unauthorized changes affecting accuracy, likely influenced the negative market sentiment and the stock's bearish movement.

07.10.2025 - DXCM Stock was down 5.1%

• The decrease in DXCM stock value might be linked to legal actions taken against the company alleging securities fraud, which has caused uncertainty among investors.
• Despite reporting strong double-digit growth in Q3 earnings and increasing its projected revenue for 2025, the stock price dropped, potentially indicating that the legal issues have overshadowed the positive financial performance.
• Investor sentiment towards DXCM appears pessimistic, possibly driven by worries concerning the lawsuits' impact on the company's image and long-term growth prospects.

31.09.2025 - DXCM Stock was down 15.0%

• Despite surpassing earnings and revenue estimates in Q3, DexCom's stock experienced a bearish movement possibly due to ongoing securities class action lawsuits.
• Investor uncertainty may have increased as investigations into potential breaches of fiduciary duties by certain officers and directors were revealed, further impacting confidence in the company.
• Analysts initially highlighted positive earnings growth potential, but the overshadowing legal issues and declining short interest may have contributed to the bearish market movement today.

31.09.2025 - DXCM Stock was down 13.7%

• The filing of class action lawsuits against DexCom Inc. by multiple law firms likely influenced the stock's bearish performance.
• Despite exceeding Q3 earnings and revenue expectations, legal issues facing the company may have dampened the impact of positive financial results.
• The decline in short interest may suggest a waning confidence or increased uncertainty among investors about the company's future trajectory.
• Legal disputes and uncertainties surrounding DexCom Inc. might have eroded investor trust, contributing to the bearish trend witnessed in the market today.

31.09.2025 - DXCM Stock was down 14.3%

• Despite strong growth in Q3 and an increase in revenue projections for 2025, DXCM saw a decline in its stock price, signaling a disconnect between its performance and investor expectations.
• An ongoing examination into potential breaches of fiduciary duties by certain company officials could have contributed to investor unease and the stock's bearish performance.
• Legal actions initiated by a law firm on behalf of DXCM investors within a specific timeframe might have added to the negative market sentiment surrounding the company.
• Even surpassing Q3 earnings and revenue forecasts may not have been enough to counterbalance overarching market apprehensions and legal uncertainties, resulting in the decline in the stock's value.

25.07.2025 - DXCM Stock was down 3.0%

• DXCM's expansion efforts and focus on innovation with type 2 access, Stelo adoption, and new sensor launches have been positive for the company.
• However, margin pressures, increasing competition, and a leadership transition may have contributed to investor concerns, leading to the bearish movement in the stock price.
• The balancing act between growth opportunities and challenges in the market could be causing uncertainty among investors, resulting in the downward trend for DXCM today.